Amedisys (NASDAQ:AMED) Earns “Equal Weight” Rating from Stephens

Stephens reissued their equal weight rating on shares of Amedisys (NASDAQ:AMED) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $101.00 price target on the health services provider’s stock.

Amedisys Price Performance

AMED opened at $92.17 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The stock’s 50 day simple moving average is $91.83 and its 200 day simple moving average is $93.05. The firm has a market cap of $3.02 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 1.78 and a beta of 0.73. Amedisys has a 1 year low of $82.15 and a 1 year high of $98.95.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. As a group, analysts predict that Amedisys will post 4.4 earnings per share for the current year.

Hedge Funds Weigh In On Amedisys

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Amedisys by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider’s stock valued at $291,992,000 after purchasing an additional 10,817 shares during the period. Pentwater Capital Management LP grew its position in shares of Amedisys by 178.3% in the 4th quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider’s stock worth $107,132,000 after buying an additional 756,000 shares during the last quarter. Westchester Capital Management LLC increased its stake in shares of Amedisys by 9.5% during the third quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock valued at $107,976,000 after buying an additional 97,476 shares during the period. Norges Bank bought a new position in shares of Amedisys during the fourth quarter valued at approximately $83,061,000. Finally, Alpine Associates Management Inc. raised its holdings in shares of Amedisys by 3.2% during the fourth quarter. Alpine Associates Management Inc. now owns 888,120 shares of the health services provider’s stock valued at $80,632,000 after acquiring an additional 27,403 shares in the last quarter. 94.36% of the stock is owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.